Recent progress in LyP-1-based strategies for targeted imaging and therapy

Drug Delivery

Ningning Song¹  Jinhua Zhao¹  Lingzhou Zhao¹  Meilin Zhu² 

[1]Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

[2]School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, People’s Republic of Chin

关键词: LyP-1;    tumor;    metastatic lesions;    atherosclerotic plaque;    diagnosis and therapeutics;   

DOI  :  10.1080/10717544.2019.1587047

来源: publisher

【 摘 要 】

The identification of markers expressed by pathological cells or their microenvironment would help to distinguish such cells from the normal tissues. The strategies derived from this theory can be a promising modality for imaging and treating diseases. LyP-1, a tumor homing peptide, can selectively bind to its receptor p32 protein overexpressed in various tumor-associated cells and atherosclerotic plaque macrophages. During recent decades, multiple types of LyP-1-based imaging probes and drug delivery systems have been designed and developed for diagnostic and therapeutic applications. This review first introduces LyP-1 and its receptor p32, as well as its homing, internalization and proapoptotic properties. Next, we highlight recent studies focusing on the applications of LyP-1-based strategies in the diagnosis and treatment of tumors, metastatic lesions, and atherosclerotic plaques. Finally, several limitations in the clinical translation of LyP-1-based bioconjugates are summarized.

【 授权许可】

CC BY